Impact of reduced chemotherapy treatment for good risk childhood acute lymphoblastic leukaemia on infectious morbidity

British Journal of Haematology

Volumn 152, Issue 4, 2011, Pages 433-440

  Van Tilburg, Cornelis M ^a   Sanders, Elisabeth A M ^a   Nibbelke, Elisabeth E ^a   Pieters, Rob ^b   Revesz, Tom ^c   Westers, Paul ^a   Wolfs, Tom F W ^a   Bierings, Marc B ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

Acute lymphoblastic leukaemia; Chemotherapy; Child; Infection; Toxicity

Indexed keywords

ANTIBIOTIC AGENT; ANTILEUKEMIC AGENT; ASPARAGINASE MACROGOL; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN; ITRACONAZOLE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; FEVER; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFECTION; LENGTH OF STAY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTPATIENT; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION;

ADOLESCENT; AMBULATORY CARE; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEVER; HOSPITALIZATION; HUMANS; INFANT; MALE; NEOPLASM, RESIDUAL; OPPORTUNISTIC INFECTIONS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78851469871     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08463.x     Document Type: Article

References (31)

1. Ammann, R.A., Bodmer, N., Hirt, A., Niggli, F.K., Nadal, D., Simon, A., Ozsahin, H., Kontny, U., Kuhne, T., Popovic, M.B., Luthy, A.R. & Aebi, C. (2010) Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. Journal of Clinical Oncology, 28, 2008-2014.
2. Badger, G.F., Dingle, J.H., Feller, A.E., Hodges, R.G., Jordan, Jr, W.S. & Rammelkamp, Jr, C.H. (1953) A study of illness in a group of Cleveland families. II. Incidence of the common respiratory diseases. American Journal of Hygiene, 58, 31-40.
3. Brimblecombe, F.S., Cruickshank, R., Maters, P.L., Reid, D.D. & Stewart, G.T. (1958) Family studies of respiratory infections. British Medical Journal, 1, 119-128.
4. Calandra, T. (1987) Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group. New England Journal of Medicine, 317, 1692-1698.
5. Cherry, J.D. & Nieves, D.J. (2009) The common cold. In: Text Book of Pediatric Infectious Diseases 1, 6th edn. (ed. by Feigin, R.D.), 1pp. 138-146. Philadelphia: Saunders.
6. Childhood Acute Lymphoblastic Leukaemia Collaborative Group (2010) Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5659 children. British Journal of Haematology, 149, 722-733.
7. Conter, V., Bartram, C.R., Valsecchi, M.G., Schrauder, A., Panzer-Grumayer, R., Moricke, A., Arico, M., Zimmermann, M., Mann, G., De, R.G., Stanulla, M., Locatelli, F., Basso, G., Niggli, F., Barisone, E., Henze, G., Ludwig, W.D., Haas, O.A., Cazzaniga, G., Koehler, R., Silvestri, D., Bradtke, J., Parasole, R., Beier, R., van Dongen, J.J., Biondi, A. & Schrappe, M. (2010) Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood, 115, 3206-3214.
8. van Dongen, J.J., Seriu, T., Panzer-Grumayer, E.R., Biondi, A., Pongers-Willemse, M.J., Corral, L., Stolz, F., Schrappe, M., Masera, G., Kamps, W.A., Gadner, H., van Wering, E.R., Ludwig, W.D., Basso, G., de Bruijn, M.A., Cazzaniga, G., Hettinger, K., van der Does-van den Berg, A., Hop, W.C., Riehm, H. & Bartram, C.R. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet, 352, 1731-1738.
9. Eyrich, M., Wiegering, V., Lim, A., Schrauder, A., Winkler, B. & Schlegel, P.G. (2009) Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia - a prospective study of 20 paediatric patients. British Journal of Haematology, 147, 360-370.
10. Flohr, T., Schrauder, A., Cazzaniga, G., Panzer-Grumayer, R., van der Velden, V., Fischer, S., Stanulla, M., Basso, G., Niggli, F.K., Schafer, B.W., Sutton, R., Koehler, R., Zimmermann, M., Valsecchi, M.G., Gadner, H., Masera, G., Schrappe, M., van Dongen, J.J., Biondi, A. & Bartram, C.R. (2008) Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia, 22, 771-782.
11. Fox, J.P., Hall, C.E., Cooney, M.K., Luce, R.E. & Kronmal, R.A. (1972) The Seattle virus watch. II. Objectives, study population and its observation, data processing and summary of illnesses. American Journal of Epidemiology, 96, 270-285.
12. Gafter-Gvili, A., Fraser, A., Paul, M., van de Wetering, M.D., Kremer, L. & Leibovici, L. (2005) Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database of Systematic Reviews, CD004386.
13. Graubner, U.B., Porzig, S., Jorch, N., Kolb, R., Wessalowski, R., Escherich, G. & Janka, G.E. (2008) Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia. PediatricBlood & Cancer, 50, 259-263.
14. Haining, W.N., Neuberg, D.S., Keczkemethy, H.L., Evans, J.W., Rivoli, S., Gelman, R., Rosenblatt, H.M., Shearer, W.T., Guenaga, J., Douek, D.C., Silverman, L.B., Sallan, S.E., Guinan, E.C. & Nadler, L.M. (2005) Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia. Blood, 106, 1749-1754.
15. Hicks, K.L., Chemaly, R.F. & Kontoyiannis, D.P. (2003) Common community respiratory viruses in patients with cancer: more than just "common colds". Cancer, 97, 2576-2587.
16. Hughes, W.T., Armstrong, D., Bodey, G.P., Bow, E.J., Brown, A.E., Calandra, T., Feld, R., Pizzo, P.A., Rolston, K.V., Shenep, J.L. & Young, L.S. (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases, 34, 730-751.
17. Kamps, W.A., van der Pal-de Bruin, K.M., Veerman, A.J., Fiocco, M., Bierings, M. & Pieters, R. (2010) Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia, 24, 309-319.
18. Koskenvuo, M., Mottonen, M., Rahiala, J., Saarinen-Pihkala, U.M., Riikonen, P., Waris, M., Ziegler, T., Uhari, M., Salmi, T.T. & Ruuskanen, O. (2008) Respiratory viral infections in children with leukemia. Pediatric Infectious Disease Journal, 27, 974-980.
19. Lehrnbecher, T., Koehl, U., Wittekindt, B., Bochennek, K., Tramsen, L., Klingebiel, T. & Chanock, S.J. (2008) Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies. The Lancet Oncology, 9, 269-278.
20. Lehrnbecher, T., Schubert, R., Behl, M., Koenig, M., Rose, M.A., Koehl, U., Meisel, R. & Laws, H.J. (2009) Impaired pneumococcal immunity in children after treatment for acute lymphoblastic leukaemia. British Journal of Haematology, 147, 700-705.
21. McNeer, J.L. & Nachman, J.B. (2010) The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. British Journal of Haematology, 149, 638-652.
22. Pui, C.H., Campana, D., Pei, D., Bowman, W.P., Sandlund, J.T., Kaste, S.C., Ribeiro, R.C., Rubnitz, J.E., Raimondi, S.C., Onciu, M., Coustan-Smith, E., Kun, L.E., Jeha, S., Cheng, C., Howard, S.C., Simmons, V., Bayles, A., Metzger, M.L., Boyett, J.M., Leung, W., Handgretinger, R., Downing, J.R., Evans, W.E. & Relling, M.V. (2009) Treating childhood acute lymphoblastic leukemia without cranial irradiation. New England Journal of Medicine, 360, 2730-2741.
23. Pui, C.H., Pei, D., Sandlund, J.T., Ribeiro, R.C., Rubnitz, J.E., Raimondi, S.C., Onciu, M., Campana, D., Kun, L.E., Jeha, S., Cheng, C., Howard, S.C., Metzger, M.L., Bhojwani, D., Downing, J.R., Evans, W.E. & Relling, M.V. (2010) Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia, 24, 371-382.
24. Schimpff, S.C., Gaya, H., Klastersky, J., Tattersall, M.H. & Zinner, S.H. (1978) Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. The Journal of Infectious Diseases, 137, 14-29.
25. Te Poele, E.M., de Bont, E.S., Marike, B.H., Revesz, T., Bokkerink, J.P., Beishuizen, A., Nijhuis, I.J., Oude Nijhuis, C.S., Veerman, A.J. & Kamps, W.A. (2007) Dexamethasone in the maintenance phase of acute lymphoblastic leukaemia treatment: is the risk of lethal infections too high? European Journal of Cancer, 43, 2532-2536.
26. Te Poele, E.M., Tissing, W.J., Kamps, W.A. & de Bont, E.S. (2009) Risk assessment in fever and neutropenia in children with cancer: what did we learn? Critical Reviews in Oncology/Hematology, 72, 45-55.
27. van Tilburg, C.M., Sanders, E.A., Rovers, M.M., Wolfs, T.F. & Bierings, M.B. (2006) Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review. Leukemia, 20, 1717-1722.
28. van Tilburg, C.M., van der Velden, V.H., Sanders, E.A., Wolfs, T.F., Gaiser, J.F., de Haas, V., Pieters, R., Bloem, A.C. & Bierings, M.B. (2010) Reduced versus intensive chemotherapy for childhood acute lymphoblastic leukemia: Impact on lymphocyte compartment composition. Leukemia Research, doi:.
29. Veerman, A.J., Kamps, W.A., van den Berg, H., van den Berg, E., Bokkerink, J.P., Bruin, M.C., van den Heuvel-Eibrink, M.M., Korbijn, C.M., Korthof, E.T., van der Pal, K., Stijnen, T., van Weel Sipman, M.H., van Weerden, J.F., van Wering, E.R. & van der Does-van den Berg, A. (2009) Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). The Lancet Oncology, 10, 957-966.
30. Vrooman, L.M., Neuberg, D.S., Stevenson, K., Supko, J.G., Sallan, S.E. & Silverman, L.B. (2009) Dexamethasone and Individualized Asparaginase Dosing Are Each Associated with Superior Event-Free Survival in Childhood Acute Lymphoblastic Leukemia: results From DFCI-ALL Concortium Protocol 00-01. Blood (ASH meeting abstracts), 114, 136.
31. Woroniecka, M. & Ballow, M. (2000) Office evaluation of children with recurrent infection. Pediatric Clinics of North America, 47, 1211-1224.